| Name | Title | Contact Details |
|---|---|---|
Anju Chatterji |
Chief Technical Officer | Profile |
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena`s proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.
Visterra is a biotechnology company that uses its proprietary Hierotope™ Platform to identify unique disease targets and design and engineer effective therapeutics. The company`s technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. The company`s lead product candidate, VIS410, is a broad spectrum human monoclonal antibody for the treatment of both seasonal and pandemic influenza, is in a phase 2a clinical trial and expected to enter a phase 2b clinical trial by year end 2017. The company`s second product candidate, VIS649, is a monoclonal antibody engineered to treat IgA nephropathy, a rare chronic kidney disease. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.
INVO Bioscience is a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our INVOcell® Culture Device is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman`s body, in vivo. This revolutionary device promotes in vivo conception. It is an FDA cleared Intravaginal Culture (IVC) device that is a safe, effective and economical fertility treatment.
Medarray is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.